Étiquette : MDMA

Reviewing the Potential of Psychedelics for the Treatment of PTSD, Erwin Krediet et al., 2020

Reviewing the Potential of Psychedelics for the Treatment of PTSD Erwin Krediet, Tijmen Bostoen, Joost Breeksema, Annette van Schagen, Torsten Passie, Eric Vermetten International Journal of Neuropsychopharmacology, 2020, 23, (6), 385–400 doi : 10.1093/ijnp/pyaa018 https://pubmed.ncbi.nlm.nih.gov/32170326/   Abstract There are few medications with demonstrated efficacy for the treatment of posttraumatic stress disorder (PTSD). Treatment guidelines have unequivocally designated psychotherapy as a first line treatment for PTSD. Yet, even after psychotherapy, PTSD often remains a chronic illness, with high rates of psychiatric and medical comorbidity. Meanwhile, the search for and development of drugs with new mechanisms of action has stalled. Therefore, there is an urgent need to explore not [...]

Lire la suite

Nouveaux produits de synthèse – Synthèse des connaissances, www.ofdt.fr, 2018

Nouveaux produits de synthèse - Synthèse des connaissances Copyright © Observatoire Français des Drogues et des Toxicomanies, mai 2018 https://www.drogues.gouv.fr/publication/nouvelles-substances-psychoactives-un-guide-services-durgences   Présentation L’abréviation NPS est généralement utilisée en France en référence aux Nouveaux Produits de synthèse. Ils désignent un éventail très hétérogène de substances qui imitent les effets de différents produits illicites (ecstasy, amphétamines, cocaïne, cannabis, etc.). Leurs structures moléculaires s’en rapprochent, sans être tout à fait identiques. Cette spécificité leur permet, au moins à court terme, de contourner la législation sur les stupéfiants ; certains sont classés, d’autres n’ont pas de statut juridique clair. Généralement achetés sur Internet, les NPS sont connus soit par leurs noms [...]

Lire la suite

BIBLIOGRAPHIE : Substances psychédéliques : Généralités, Épistémologie, Pharmacologie, Neurophysiologie, Psychologie…, Dr Christian SUEUR, GRECC, mai 2020 (nouvelle version)

BIBLIOGRAPHIE : Substances psychédéliques : Généralités, Épistémologie, Pharmacologie, Neurophysiologie, Psychologie, … Dr Christian SUEUR, GRECC, mai 2020 (nouvelle version)   Substances psychédéliques : Généralités, Pharmacologie, Neurophysiologie : 1 - 17 Substances psychédéliques et «psychologie » : 18 - 20   Cf également : Bibliographie : Thérapies psychédéliques, Bibliographie : Substances psychédéliques, culture, chamanisme, spiritualité, religion… Bibliographie : Psilocybine, Bibliographie : LSD, Bibliographie : Ayahuasca, Bibliographie : Mescaline et Peyotl, Bibliographie : MDMA, Bibliographie : Tryptamines …

Lire la suite

MDMA-Induced Dissociative State not Mediated by the 5-HT2A Receptor, Drew J. Puxty et al., 2017

MDMA-Induced Dissociative State not Mediated by the 5-HT2A Receptor Drew J. Puxty, Johannes G. Ramaekers, Rafael de la Torre, Magí Farré, Neus Pizarro, Mitona Pujadas and Kim P. C. Kuypers Frontiers in Pharmacology, 2017, Volume 8, Article 455 Doi : 10.3389/fphar.2017.00455   Previous research has shown that a single dose of MDMA induce a dissociative state, by elevating feelings of depersonalization and derealization. Typically, it is assumed that action on the 5-HT2A receptor is the mechanism underlying these psychedelic experiences. In addition, other studies have shown associations between dissociative states and biological parameters (heart rate, cortisol), which are elevated by MDMA. In order to investigate [...]

Lire la suite

Psychedelics for Mental Illness: The Evidence to Date, Todd Murphy, 2020

Psychedelics for Mental Illness: The Evidence to Date Todd Murphy Medscape, 12 March, 2020. https://www.medscape.com/viewarticle/926694_print Psychedelic drugs show real promise as treatment for psychiatric illnesses, particularly posttraumatic stress disorder (PTSD) as well as depression and anxiety, new research suggests. A literature review showed completed clinical trials support the efficacy of 3, 4-methylenedioxymethamphetamine (MDMA), commonly known by its street name of Ecstasy, to treat chronic PTSD. The review also confirmed that psilocybin, a compound contained in some species of mushrooms, significantly helped in the treatment of depression and cancer-related anxiety. Other promising, though more preliminary, results suggests that the hallucinogenic drug LSD (lysergic acid diethylamide) and a plant-based brew [...]

Lire la suite

Psychedelics and Psychedelic-Assisted Psychotherapy, Collin M. Reiff et al., 2019

Psychedelics and Psychedelic-Assisted Psychotherapy Collin M. Reiff, M.D., Elon E. Richman, M.D., Charles B. Nemeroff, M.D., Ph.D., Linda L. Carpenter, M.D., Alik S. Widge, M.D., Ph.D., Carolyn I. Rodriguez, M.D., Ph.D., Ned H. Kalin, M.D., William M. McDonald, M.D., and the Work Group on Biomarkers and Novel Treatments, a Division of the American Psychiatric Association Council of Research AJP in Advance, 2019, 1-20. doi: 10.1176/appi.ajp.2019.19010035   Objective : The authors provide an evidenced-based summary of the literature on the clinical application of psychedelic drugs in psychiatric disorders. Methods : Searches of PubMed and PsycINFO via Ovid were conducted for articles in English, in peer-reviewed journals, reportingon“psilocybin,” [...]

Lire la suite

Posttraumatic Growth After MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder, Ingmar Gorman et al., 2020

Posttraumatic Growth After MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder Ingmar Gorman, Alexander B. Belser, Lisa Jerome, Colin Hennigan, Ben Shechet, Scott Hamilton, Berra Yazar-Klosinski, Amy Emerson, and Allison A. Feduccia Journal of Traumatic Stress, 2020, 1-10. Doi : 10.1002/jts.22479   3,4-Methylenedioxymethamphetamine (MDMA)–assisted psychotherapy for posttraumatic stress disorder (PTSD) has been shown to significantly reduce clinical symptomatology, but posttraumatic growth (PTG), which consists of positive changes in self-perception, interpersonal relationships, or philosophy of life, has not been studied with this treatment. Participant data (n = 60) were pooled from three Phase 2 clinical studies employing triple-blind crossover designs. Participants were required to meet DSM-IV-R criteria for [...]

Lire la suite

Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline, Allison A. Feduccia et al., 2019

Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline Allison A. Feduccia, Lisa Jerome, Berra Yazar-Klosinski, Amy Emerson, Michael C. Mithoefer and Rick Doblin Frontiers in Psychiatry, 2019, Volume 10, Article 650. doi: 10.3389/fpsyt.2019.00650   Unsuccessfully treated posttraumatic stress disorder (PTSD) is a serious and lifethreatening disorder. Two medications, paroxetine hydrochloride and sertraline hydrochloride, are approved treatments for PTSD by the Food and Drug Administration (FDA). Analyses of pharmacotherapies for PTSD found only small to moderate effects when compared with placebo. The Multidisciplinary Association for Psychedelic Studies (MAPS) obtained Breakthrough Therapy Designation (BTD) from the FDA for 3,4 methylenedioxymethamphetamine [...]

Lire la suite

Reported effects of psychedelic use on those with low well-being given various emotional states and social contexts, Natasha L. Mason et al., 2020,

Reported effects of psychedelic use on those with low well-being given various emotional states and social contexts Natasha L. Mason, Patrick C. Dolder and Kim P.C. Kuypers Drug Science, Policy and Law, 2020, Volume 6, 1–11. Doi : 10.1177/2050324519900068   Abstract Background : It has been suggested that the outcome of the psychedelic experience is dependent on set and setting. While scientific research into the therapeutic potential of psychedelics is growing, it is clear that in clinical populations an optimal set and setting will not always be attainable. It was aimed to assess under which emotional and environmental circumstances psychedelic users use psychedelics, and the outcome [...]

Lire la suite

Comment microdoser du LSD m’aide à gérer mon autisme, Charlie Ellis, Vice, 08 Janvier 2020

Comment microdoser du LSD m'aide à gérer mon autisme Charlie Ellis Vice, 08 Janvier 2020 https://www.vice.com/fr/article/4agd7d/comment-microdoser-du-lsd-maide-a-gerer-mon-autisme "Je prends fréquemment de très petites quantités de psychédélique pour combler le fossé avec les personnes neurotypiques." C’est toujours le même rituel. J’aime les rituels, ils rationalisent l’absurdité de nos existences et me permettent de continuer à vivre. Réveil engourdi, lavage de mains compulsif, 20 grammes de café et 15 microgrammes de LSD sous la langue. Je suis prête à affronter le monde neurotypique – le monde de ceux qui ne sont pas autistes. Je suis autiste. Je pense, ressens et traite les informations de manière complètement différente. J’ai [...]

Lire la suite